PwC Cuts Weight-Loss Drug Coverage for Staff

PwC will no longer cover the cost of weight-loss drugs for its US employees unless they have a diabetes diagnosis. This policy change, set to take effect in July, emerged as employees attempted to renew their annual benefits, leading to significant discontent.

The accounting and consulting firm stated that its health insurance will cease covering GLP-1 medications for weight loss, weight management, and related conditions. PwC indicated this move aligns with broader industry trends and the necessity to control rapidly escalating costs while preserving access to clinically vital treatments.

This decision follows a growing number of companies implementing restrictions on these expensive medications. For instance, Blue Cross Blue Shield of Massachusetts also ended GLP-1 coverage for its staff unless they had diabetes, deeming it unsustainable otherwise. The popularity of these drugs has surged, making them the top-selling medicines in the pharmaceutical sector, despite their high cost for insurance plans.

PwC has noted the complex implications of such coverage decisions, which can affect workforce health, plan sustainability, and employee trust. The company emphasized its commitment to monitoring the external landscape to make thoughtful, sustainable benefits choices that broadly support its workforce.